Granatus Ventures Invests in Endometrics to Develop First-in-Kind Solution to Endometriosis

2 min read

Granatus Ventures, a leading venture capital firm, has announced its recent investment in Endometrics, a medtech company specializing in developing a revolutionary non-invasive diagnostic solution for endometriosis.

Manuk Hergnyan and Yana Aznavour — Manuk Hergnyan, Managing Partner at Granatus Ventures, and Yana Aznavour, CEO and founder of Endometrics.

Endometriosis is a chronic condition that affects women causing severe pain and infertility. It affects around 10% of women of reproductive age, diagnosis takes up to 8 years and requires surgery. Endometrics develops a unique solution for diagnosing endometriosis non-invasively by identifying specific genomic features of endometrial cells.

Endometrics, led by award-winning ObGyn and researcher Yana Aznavour, has joined Granatus Ventures’ portfolio of deep tech companies. Dr. Aznavour expressed excitement about the partnership, stating that Granatus Ventures’ capital and network would help Endometrics advance to the next stage. With this support, Endometrics can introduce its diagnostic solution to the market and achieve new levels of growth.

Manuk Hergnyan, Managing Partner at Granatus Ventures, sees great potential in this partnership, emphasizing their commitment to supporting Endometrics’ groundbreaking diagnostic solution to alleviate the suffering of so many women around the world.

The investment from Granatus Ventures will accelerate the development and launch of Endometrics’ innovative solution, expand its marketing efforts, and hire additional talent to support its growth.

About Granatus Ventures

Granatus Ventures is a leading venture capital firm based in Yerevan, Armenia. The firm invests in deep tech startups that address the most fundamental global issues.

About Endometrics

Endometrics, a Berkeley-based company with the team in Armenia, is committed to transforming women’s healthcare, starting with endometriosis. Endometrics recently graduated from the UC Berkeley accelerator and received the first-prize award in the emerging startup category at the Women’s Health Innovation Summit Startup Showcase.

Generative A.I. Arrives in the Gene Editing World of CRISPR

Much as ChatGPT learns to generate language by analyzing Wikipedia articles, books and chat logs, Profluent’s technology creates new gene editors after analyzing enormous amounts of biological data, including microscopic mechanisms that scientists already use to edit human DNA.

Read post

‘If You Could Hallucinate a Protein’: Profluent Snags $35M for Generative AI Models

In January 2023, Profluent’s large language model was detailed in a Nature Biotechnology paper, showing that it could create new proteins that functioned like ones found in nature. The upstart was founded by CEO Ali Madani, a former leader of machine learning work at Salesforce Research, and University of Washington School of Medicine assistant professor Alexander Meeske.

Read post

Meet The Disruptors: Anil Narasimha Of Mekonos On The Five Things You Need To Shake Up Your Industry

"Anytime you want to be a disruptor in a space, you have to start by understanding what the status quo is in that space, because sometimes it can be a moving target. Sometimes if you haven’t defined the status quo properly, you can go down a rabbit hole that you don’t necessarily need to go down."

Read post

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing

“Our research at the forefront of AI has enabled Profluent to create large language models that begin to learn the blueprint of nature,” said Ali Madani, Profluent co-founder and Chief Executive Officer. “We are moving biology from being constrained by what can be discovered in nature to being able to design precisely according to our needs via AI. The science is real and the time is now to proactively create breakthrough medicines that can transform society.”

Read post

Granatus Ventures Invests in Endometrics to Develop First-in-Kind Solution to Endometriosis

News Updates

Learn More

Generative A.I. Arrives in the Gene Editing World of CRISPR

Minutia Wins $1.2M Grant from CIRM for “Immune Cloaking of Human Stem Cell-Derived Insulin Producing Cells”

‘If You Could Hallucinate a Protein’: Profluent Snags $35M for Generative AI Models

Meet The Disruptors: Anil Narasimha Of Mekonos On The Five Things You Need To Shake Up Your Industry

Funding Success for Seaweed-Based Bacon Startup

Profluent Secures $35M in Additional Funding and Key Industry Experts to Scale Foundational AI Models for Biomedicine and Tackle First Vertical in Gene Editing